Similarly, many other studies investigating the response to neoadjuvant HER2 targeted therapy have shown that high HER2 levels [16, 40], HER2/CEP17 ratio > 6 [41], high baseline tumor infiltrating lymphocytes [42] and HER2-enriched molecular subtype [43] are all associated with a significantly higher pCR rate. This evidence concerns the gene ERBB2 and neoplasm.